Sprint Bioscience
Pharmaceutical ManufacturingStockholm, Sweden11-50 Employees
Sprint Bioscience is an innovative company focused on early-stage drug development, providing novel drug candidates within the cancer field.
Strong Industry Focus Sprint Bioscience specializes in early-stage cancer drug development, presenting opportunities to collaborate with pharmaceutical companies seeking innovative oncology candidates or licensing promising assets.
Recent Asset Divestment The sale of a major cancer program to Gilead Sciences for 414 million USD indicates significant valuation and potential for partnership in high-value oncology therapeutics, making them a key player for licensing or acquisition discussions.
Strategic Collaborations Partnerships with entities like the Experimental Drug Development Centre and Day One Biopharmaceuticals highlight opportunities for joint research, co-development, or technology licensing to accelerate drug discovery processes.
Emerging Focus Areas Expansion into inflammatory diseases and AML through new drug programs opens doors for suppliers of research tools, clinical trial services, and targeted treatments tailored to these indications.
Growing R&D Investment With moderate revenue and recent funding around 2.3 million USD, Sprint Bioscience is actively investing in innovation, creating potential for sales of research services, laboratory equipment, or specialized compounds to support their development programs.
Sprint Bioscience uses 8 technology products and services including Linkedin Sign-in, jQuery, Google Maps, and more. Explore Sprint Bioscience's tech stack below.
| Sprint Bioscience Email Formats | Percentage |
| First.Last@sprintbioscience.com | 50% |
| First.Last@sprintbioscience.com | 50% |
Pharmaceutical ManufacturingStockholm, Sweden11-50 Employees
Sprint Bioscience is an innovative company focused on early-stage drug development, providing novel drug candidates within the cancer field.
Sprint Bioscience has raised a total of $2.3M of funding over 4 rounds. Their latest funding round was raised on Mar 15, 2016 in the amount of $2.3M.
Sprint Bioscience's revenue is estimated to be in the range of $1M$10M
Sprint Bioscience has raised a total of $2.3M of funding over 4 rounds. Their latest funding round was raised on Mar 15, 2016 in the amount of $2.3M.
Sprint Bioscience's revenue is estimated to be in the range of $1M$10M